微创科学（Microport Scientific）近日发布业绩公告，其旗下核心企业——上海心脉医疗科技（集团）股份有限公司（Shanghai Microport Endovascular Medtech）在最新财年表现亮眼。根据披露数据，心脉医疗全年实现归属母公司股东的净利润为5.632亿元人民币。
这一业绩凸显了心脉医疗在血管介入医疗器械领域的持续领先地位与稳健的盈利能力。作为微创科学的重要组成部分，心脉医疗的强劲表现也为集团整体发展注入了积极动力。
微创科学（Microport Scientific）近日发布业绩公告，其旗下核心企业——上海心脉医疗科技（集团）股份有限公司（Shanghai Microport Endovascular Medtech）在最新财年表现亮眼。根据披露数据，心脉医疗全年实现归属母公司股东的净利润为5.632亿元人民币。
这一业绩凸显了心脉医疗在血管介入医疗器械领域的持续领先地位与稳健的盈利能力。作为微创科学的重要组成部分，心脉医疗的强劲表现也为集团整体发展注入了积极动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.